The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Myeloid-derived suppressor cell (MDSC) kinetics following acalabrutinib and pembrolizumab treatment in platinum-resistant metastatic urothelial carcinoma (mUC).
 
Kristen A Batich
Patents, Royalties, Other Intellectual Property - Patent US20160271240A1
 
Janet S. Staats
No Relationships to Disclose
 
Cliburn Chan
No Relationships to Disclose
 
Cecile Krejsa
Employment - Acerta Pharma
Stock and Other Ownership Interests - Acerta Pharma; AstraZeneca; Seagen
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Kent J. Weinhold
Consulting or Advisory Role - Merck
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma